Skip to NavigationSkip to content

Business Services

Pharma disputes, fines, and the work of the CMA

Published on 25/08/21 at 10:32am

Several pharmaceutical firms have lately been fined for unfairly hiking prices over the years, meaning that patients and the NHS have suffered. Lilly Subbotin spoke with Andrew Groves, Director for Antitrust at the Competition and Markets Authority (CMA), and pharma disputes lawyer, Emma Ruane, to see how the CMA will be cracking down and why pharma firms should be on high alert

Vaccines Virtual Conference 2021

Two shots of Pfizer or AstraZeneca vaccine are effective against Delta variant

A new study has shown that two shots of either Pfizer or AstraZeneca’s COVID-19 vaccine are nearly as effective against the Delta variant as they are against the previously dominant Alpha variant.

The study, published in the New England Journal of Medicine, confirms headline findings given by Public Health England in May about the efficacy of COVID-19 vaccines made by Pfizer-BioNTech and Oxford-AstraZeneca based on real-world data.

Roche discussing potential Alzheimer’s treatment with FDA

Roche is discussing its potential treatment, gantenerumab, for Alzheimer's disease with the FDA as clinical trials proceed.

Chief Executive Severin Schwan said Roche will complete a Phase-III trial of the medicine in the second half of next year.

He cited the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.

Analysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.

NICE approves treatment for rare bile duct cancer

NICE has approved Pemigatinib (Pemazyre) as first treatment for people with a rare form of bile duct cancer (cholangiocarcinoma).

Pemigatinib, made by the Incyte Corporation, is recommended for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement.

The treatment is an option for adults whose cancer has progressed after chemotherapy, around 50 people will be eligible for the treatment.

PMPS and FlyPharma – COVID-19 Free Webinar

PrecisionLife appoints Ray Pawlicki as Executive Chair to the board of directors

Published on: 30/06/21

PrecisionLife Limited has appointed Ray Pawlicki, previously CIO at Biogen and Novartis, as Executive Chair to the board of directors.

Widely recognised as a leader in informatics across pharma and biotech, Ray will work closely with the PrecisionLife Board and CEO Steve Gardner to help steer the strategic growth of the company.

New Chief Operating Officer for Dutch MedTech STENTiT

Published on: 30/06/21

Medical device company STENTiT has appointed Dr Golo von Basum as its Chief Operating Officer.

He will be responsible for the strategic implementation to scale and standardise the product development and company operations. Golo brings more than 16 years of experience in medical device development, having worked as Site Leader and Head of R&D of several departments within Philips.

Christian Dillon announced as Vice President of Biology at PhoreMost

Published on: 30/06/21

PhoreMost has announced the appointment of Dr Christian Dillon as Vice President of Biology.

In this new role, Dr Dillon will work across all the company’s areas of interest, including oncology, targeted protein degradation, and neurodegeneration. Dillon joins PhoreMost from Cancer Research UK’s Therapeutic Discovery Laboratories where he was Associate Director, acting as programme director for multiple drug discovery alliances with pharmaceutical partners, leading both discovery projects and portfolios from concept through to candidate nomination.

Ashfield Engage appoints new Head of Patient Solutions

Published on: 30/06/21

Ashfield Engage, part of UDG Healthcare plc, has appointed Serap Becker as Head of Patient Solutions for the DACH region.

Joining the Ashfield Engage team following three years as Director of Direct to Patient Services at Marken, Serap has 20 years of experience in clinical trials and a customer-driven focus.

Serap will report into Benjamin Rapp, Regional President EU South, and will oversee services including patient engagement programmes, education and training, health outcomes, and patient support programme consulting and solution design in the region.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches